Managing Antitrust Risks in Pre-Transaction Planning

By Theresa C. Carnegie

Dynamic changes in the nation’s health care delivery systems have been prompted, in part, by the implementation of the Patient Protection and Affordable Care Act (“ACA”). In the wake of the ACA, hospitals and other health care industry participants have been undergoing significant consolidation.  Health care antitrust enforcers continue to closely scrutinize health care transactions in order to ensure that new health care delivery systems do not enhance or create market power or otherwise harm consumers.  As such, there are certain steps deal counsel should take in order to effectively manage and minimize potential antitrust risks in transactions with competitors.

In part one of a three part series, my colleagues, Dionne Lomax and Farrah Short, offer a planning checklist for transactions with potential competitive concerns.

Subscribe To Viewpoints

Published

    • Viewpoint Topics

  • Health Care

    • Professionals

  • Theresa C. Carnegie

    • Author

    Theresa C. Carnegie

    Member

    Theresa advises clients on all aspects of the pharmaceutical supply chain, including counseling industry stakeholders on a range of business, legal, transactional, and compliance matters. She provides clients with strategic counseling and creative business modeling that considers legal restrictions and regulatory risk in light of innovation and business goals.